Abstract
ADP plays a key role in platelet aggregation which has led to the development of antiplatelet drugs that target the P2Y(12) receptor. The aim of this study was to characterize the effects of two novel P2Y(12) receptor antagonists, BX 667 and its active metabolite BX 048, on platelets. BX 667 and BX 048 block the binding of 2MeSADP to platelets and antagonize ADP-induced platelet aggregation in human, dog and rat washed platelets. Both compounds were shown to be reversible inhibitors of platelet aggregation. BX 048 prevents the decrease in cAMP induced by treatment of platelets with ADR The specificity of BX 667 and BX 048 was demonstrated against cell, lines expressing P2Y(1) and P2Y(6) as well as against a panel of receptors and enzymes. Taken all together these data show that both BX 048 and BX 667 are potent P2Y(12) antagonists with high specificity which, in the accompanying paper are demonstrated to behave predictably in vivo. (C) 2008 Elsevier Ltd. All rights reserved.